Abstract
No public abstract is available from the verified source records.
Alfonso Ielasi, Elisabetta Moscarella, Gregor Verček, Christian Frerker, Luca Testa, Alexander Ijsselmuiden, Francesco Maisano, Gioel Gabrio Secco, Emanuele Cigala, Didier Tchetche, Sengottuvelu Gunasekaran, Antonio Micari, Marco Gennari, Paolo Calabrò, Emilio Di Lorenzo, Praveen Chandra, Ashok Seth, Matjaž Bunc
Abstract
Authors
No local reference links have been materialized yet.
No local citing links have been materialized yet.
ESC/EACTS guidelines for the management of valvular heart disease
10.1093/eurheartj/ehaf194 · 2025
Comparing two-year outcomes of balloon-expandable Myval and self-expanding Evolut R in severe aortic valve stenosis
10.1016/j.ijcard.2023.131701 · 2024
Transcatheter valve-in-valve or valve-in-ring implantation with a novel balloon-expandable device in patients with bioprosthetic left side heart valves failure: 1-year follow-up from a multicenter experience
10.1016/j.ijcard.2023.01.017 · 2023
Safety and effectiveness of the novel Myval Octacor transcatheter heart valve in severe, symptomatic aortic valve stenosis - a real-world Indian experience (the OCTACOR India study)
10.1016/j.carrev.2024.01.016 · 2024
Balloon-expandable Myval Octacor versus self-expanding Evolut PRO/PRO+ and Acurate Neo2: short-term outcomes from propensity-matched analysis
2025
Immediate and early outcomes following Myval Octacor transcatheter heart valve implantation for the treatment of patients with severe aortic valve stenosis: the OCTACOR-EU study
2025
LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial
10.1016/s0140-6736(24)00821-3 · 2024
1-year outcomes of novel balloon-expandable vs contemporary transcatheter heart valves in severe aortic stenosis: the LANDMARK trial
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
10.1016/j.jacc.2025.10.076 · 2026
SAPIEN 3 versus Myval transcatheter heart valves for transcatheter aortic valve implantation (COMPARE-TAVI 1): a multicentre, randomised, non-inferiority trial
10.1016/s0140-6736(25)00106-0 · 2025
Neocommissural/coronary alignment with a novel balloon expandable transcatheter aortic valve: first-in-human experience
10.1016/j.jcin.2023.07.012 · 2023
Self-expanding or balloon-expandable TAVR in patients with a small aortic annulus
10.1056/nejmoa2312573 · 2024
Patient-tailored aortic valve replacement
10.3389/fcvm.2021.658016 · 2021
Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research
10.1016/j.jacc.2021.02.038 · 2021
ESC guidelines on cardiac pacing and cardiac resynchronization therapy
10.1093/eurheartj/ehab364 · 2021
Assessing the novel myval balloon-expandable valve with the evolut valve: a propensity-matched study
10.3390/jcm12134213 · 2023
Predictors and 5-year clinical outcomes of pacemaker after TAVR: analysis from the PARTNER 2 SAPIEN 3 registries
10.1016/j.jcin.2024.03.034 · 2024
Anatomical and functional predictors of permanent pacemaker implantation after transcatheter aortic valve implantation
2025
Cusp overlap versus standard three-cusp technique for self-expanding Evolut transcatheter aortic valves
10.4244/eij-d-22-01030 · 2023
No additional external references are available.